News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Advertise
Talent Solutions
Post Jobs
Submit a Press Release
Submit an Event
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Advertise
Talent Solutions
Post Jobs
Submit a Press Release
Submit an Event
Search Query
Submit Search
News
Drug Development
Newron Pharmaceuticals Says Phase II Study Show Painkiller Ralfinamide Improves Quality of Life
July 17, 2007
|
1 min read
Twitter
LinkedIn
Facebook
Email
Print
ZURICH (Thomson Financial) - Newron Pharmaceuticals SpA said its painkiller ralfinamide improved patients' quality of life compared to a placebo in phase II clinical tests.
Twitter
LinkedIn
Facebook
Email
Print
Clinical research
Phase 2
Europe
MORE ON THIS TOPIC
Obesity
Wave Stock Cut in Half on Underwhelming Higher Dose Obesity Data
March 26, 2026
·
2 min read
·
Tristan Manalac
Rare diseases
Beam’s Base Editor Advances to Pivotal Development on Back of ‘Impressive’ AATD Data
March 26, 2026
·
1 min read
·
Tristan Manalac
Pipeline
Sarepta Pushes Past Gene Therapy Debacle as RNA Therapies Show Early Promise
March 26, 2026
·
2 min read
·
Tristan Manalac
Insights
Beyond Buzzwords in Longevity Investing
March 26, 2026
·
1 min read
·
Jennifer C. Smith-Parker
